Andrew Higgins, MD
Cardiovascular Disease · Cleveland, OHNPI 1962760819
Payments from drug & device makers
Across 45 payments — averaging $238.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$9K
- Abiomed$405
- Getinge USA Sales, LLC$194
- Impulse Dynamics (USA) Inc.$171
- Teleflex LLC$144
- Boston Scientific$134
- plus $210 from 4 others
What the payments were for
- Speaking & faculty fees$7,21967%
- Travel & lodging$1,36913%
- Food & beverage$1,93718%
- Education$2152%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 27 | $9,481 |
| Abiomed | 5 | $405 |
| Getinge USA Sales, LLC | 3 | $194 |
| Impulse Dynamics (USA) Inc. | 2 | $171 |
| Teleflex LLC | 1 | $144 |
| Boston Scientific | 1 | $134 |
| Alnylam Pharmaceuticals Inc. | 1 | $115 |
| Angiodynamics, Inc. | 2 | $58 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $23 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$8,092
- CARDIOMEMS$800
- HeartMate 3 Left Ventricular Dev$215
- Arrow$144
- OPTIMIZER$144
- Impella$138
- WATCHMAN FLX$134
- AMVUTTRA$115
- CARDIOHELP$112
How this compares
$10,739 in reported general payments places this provider in the 75th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 85 | $2,391,776 |
| VyndaqelTafamidis Meglumine | 49 | $1,030,432 |
| EntrestoSacubitril/Valsartan | 188 | $277,614 |
| JardianceEmpagliflozin | 156 | $214,234 |
| EliquisApixaban | 45 | $57,210 |
| FarxigaDapagliflozin Propanediol | 34 | $35,986 |
| XareltoRivaroxaban | 12 | $9,006 |
| Metoprolol Succinate | 133 | $2,633 |
| Eplerenone | 21 | $2,400 |
| Torsemide | 73 | $1,234 |
| Spironolactone | 145 | $1,172 |
| Atorvastatin Calcium | 62 | $662 |
| Valsartan | 48 | $651 |
| ClopidogrelClopidogrel Bisulfate | 34 | $544 |
| Carvedilol | 90 | $519 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Cleveland
- Samir KapadiaCleveland$11.1M
- Steven NissenCleveland$5.3M
- Milind DesaiCleveland$5M
- Abraham LincoffCleveland$3.6M
- Carlos HubbardCleveland$3.1M
- Guilherme AttizzaniCleveland$2.8M
- Wai Hong TangCleveland$2.2M
- Mazen HannaCleveland$1.6M
- Daniel CantillonCleveland$1.3M
- Oussama WazniCleveland$665K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.